Skip to content
Dendreon
  • News
  • Contact Us
  • About
  • Science and Services
    • Cellular Therapy Manufacturing
    • Provenge Immunotherapy
  • Publications
  • Careers
News Largest Real-World Study Of Immunotherapy Shows Men With Advanced Prostate Cancer With Low PSA Had A Median Survival Of Nearly Four Years After Treatment With PROVENGE® (Sipuleucel-T)
September 4, 2019

Largest Real-World Study Of Immunotherapy Shows Men With Advanced Prostate Cancer With Low PSA Had A Median Survival Of Nearly Four Years After Treatment With PROVENGE® (Sipuleucel-T)

  • News Type: Press Releases
Read More
LinkedInShareTweet
Dendreon
© Dendreon Pharmaceuticals LLC. All Rights Reserved. 2023.
  • Privacy Policy
  • Legal Notice
  • Site Map
  • Linkedin
  • Facebook
  • Twitter